Development of a validated patient-reported symptom metric for pediatric Eosinophilic Esophagitis: qualitative methods

BMC Gastroenterology

Research Article

Kevin A Hommel¹  Allison B Greenberg²  James W Varni³  J Pablo Abonia⁴  Alexandria J Greenler⁴  Marc E Rothenberg⁴  Charles W DeBrosse⁴  James P Franciosi⁵ 

[1] Center for the Promotion of Treatment Adherence and Self-Management, Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA;Clinical Trials Office, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA;Department of Pediatrics, College of Medicine, Department of Landscape Architecture and Urban Planning, College of Architecture, Texas A&M University, College Station, TX, USA;Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA;Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA;

关键词: Recall Period;    Cognitive Interview;    Eosinophilic Esophagitis;    Ciclesonide;    Parent Proxy;   

DOI  :  10.1186/1471-230X-11-126

 received in 2011-04-07, accepted in 2011-11-18,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundPrevious attempts to measure symptoms in pediatric Eosinophilic Esophagitis (EoE) have not fully included patients and parents in the item development process. We sought to identify and validate key patient self-reported and parent proxy-reported outcomes (PROs) specific to EoE.MethodsWe developed methodology for focus and cognitive interviews based on the Food and Drug Administration (FDA) guidelines for PROs, the validated generic PedsQL™ guidelines, and the consolidated criteria for reporting qualitative research (COREQ). Both child (ages 8-12 and 13-18) and parent-proxy (ages 2-4, 5-7, 8-12, and 13-18) interviews were conducted.ResultsWe conducted 75 interviews to construct the new instrument. Items were identified and developed from individual focus interviews, followed by cognitive interviews for face and content validation. Initial domains of symptom frequency and severity were developed, and open-ended questions were used to generate specific items during the focus interviews. Once developed, the instrument construct, instructions, timeframe, scoring, and specific items were systematically reviewed with a separate group of patients and their parents during the cognitive interviews.ConclusionsTo capture the full impact of pediatric EoE, both histologic findings and PROs need to be included as equally important outcome measures. We have developed the face and content validated Pediatric Eosinophilic Esophagitis Symptom Score (PEESS™ v2.0). The PEESS™ v2.0 metric is now undergoing multisite national field testing as the next iterative instrument development phase.

【 授权许可】

CC BY   
© Franciosi et al; licensee BioMed Central Ltd. 2011